BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 26, 2009
 |  BioCentury  |  Emerging Company Profile

Epitarget: Bombarding Tumors with Sound

Liposomes are attractive delivery agents for chemotherapeutics because they preferentially accumulate in tumors, thereby minimizing the effects of their drug payload on healthy tissue. But existing liposome technologies release only a fraction of that payload inside the tumor, limiting the effectiveness of the therapy.

Epitarget A/S has gotten around this problem by developing ultrasound-activated liposomes. The company has data from in vitro studies showing its liposomes release more doxorubicin than Caelyx (Doxil - U.S.), a marketed liposomal doxorubicin from Johnson & Johnson and Schering-Plough Corp.

The hope is that by increasing the amount of drug delivered to solid tumors, the technology could improve the therapeutic index of novel or generic chemotherapies and extend the life of drugs about to go off patent.

"We have not found...

Read the full 632 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >